ACTRN12608000606381
已完成
未知
An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of acromegaly when administered by patients or their partners (Home Injection Group) or administered by healthcare professionals.
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Acromegaly
- 发起方
- Ipsen Pty Ltd
- 入组人数
- 38
- 状态
- 已完成
- 最后更新
- 6年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients on a stable dose of Somatuline Autogel for at least 4 months and with a diagnosis of Acromegaly.
排除标准
- •Patients who are pregnant or breastfeeding.
结局指标
主要结局
未指定
相似试验
已完成
不适用
Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of neuroendocrine tumours.euroendocrine TumoursNeuroendocrine TumoursCancer - Neuroendocrine tumour (NET)ACTRN12609000226202Ipsen Pty Ltd25
已完成
4 期
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India (Lead-In)Health Condition 1: null- Diabetes Mellitus, Type 2Health Condition 2: E11- Type 2 diabetes mellitusCTRI/2010/091/001280ovo Nordisk India Private Ltd1,386
招募中
4 期
Study to assess effectiveness of indacaterol in COPD patients in real life settingsHealth Condition 1: null- COPDCTRI/2013/09/004004ovartis Healthcare Private Limited4,500
已完成
4 期
observational study in patients with hypertensioCTRI/2018/03/012787Dr Reddys Laboratories Ltd500
已完成
4 期
observational study in patients with blood pressureHealth Condition 1: I10- Essential (primary) hypertensionHealth Condition 2: null- Male and female treatment naïve patients, aged 18â??80 years, with diagnosis of Stage II essential hypertension (DBP 100â??114 mm Hg and SBP 160â??199mm Hg)CTRI/2018/02/011727Dr Reddys Laboratories Ltd600